The 2023 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Course Chairs

Roger J. Bedimo, MD, MS
University of Texas Southwestern Medical Center
Laura W. Cheever, MD, ScM
The Health Resources and Services Administration
Michael S. Saag, MD
University of Alabama at Birmingham

Faculty

Jean Anderson, MD
The Johns Hopkins University
Jason Baker, MD, MS, FIDSA
Hennepin Healthcare
Constance A. Benson, MD
University of California San Diego
Connie L. Celum, MD, MPH
University of Washington
Meredith E. Clement, MD
Louisiana State University Health Sciences Center
Francine Cournos, MD
Francine Cournos, MD
Columbia University
Ellen F. Eaton, MD
University of Alabama at Birmingham
Christopher Evans, MD, MPH
Oregon Health & Science University
Steven K. Grinspoon, MD
Harvard Medical School
Steven C. Johnson, MD
University of Colorado School of Medicine
Nadine Kaslow
Nadine J. Kaslow, PhD
Emory University
Richard Koup, MD
Vaccine Research Center, NIAID, NIH
Hyman Scott, MD, MPH
University of California San Francisco
David H. Spach, MD
University of Washington
Victor G. Valcour, MD, PhD
University of California San Francisco

December 3-5, 2023

Portland, Oregon

Address

The Hilton Portland Downtown
921 SW Sixth Avenue
Portland
Oregon
97204
United States

Overview

2023 RWHAP CLINICAL CONFERENCE Description

The 2023 Ryan White HIV/AIDS Program (RWHAP) CLINICAL CONFERENCE will be held in-person in Portland, Oregon, from Sunday, December 3, to Tuesday, December 5. The RWHAP CLINICAL CONFERENCE will provide state-of-the-art updates on research, care, and treatment issues in the medical management of HIV infection for experienced HIV clinical decision makers.

The 2023 RWHAP CLINICAL CONFERENCE is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society-USA (IAS-USA). This conference is coordinated through the RWHAP AIDS Education and Training Centers (AETC) clinician training network.

Participation of clinical decision makers from RWHAP-funded clinics and programs in this educational activity is an integral part of HRSA’s commitment to improving the care and enriching the lives of individuals with HIV. A mix of lectures, case-based interactive presentations, and small-group workshop breakout sessions will be held during the 3 days of the 2023 RWHAP CLINICAL CONFERENCE.

Who Should Attend

Attendance is exclusively reserved for HIV clinical decision makers, primarily physicians, nurse practitioners, and physician assistants in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs (specifically those operating under part A, B, C, and D), who are responsible for direct patient care and the decisions on clinical care and practice carried out at their clinics.

For those clinics that do not have clinical decision makers or do not have one available at the time to participate, the 2023 RWHAP CLINICAL CONFERENCE offers a limited number of registration spots open specifically for pharmacists and registered nurses who play crucial roles in making clinical decisions within their respective RWHAP-funded clinics or programs. Interested pharmacists and registered nurses should register early since these spots are on a first-come basis.

A key element of the CLINICAL CONFERENCE and integral to HRSA’s commitment to supporting clinicians is that participants from RWHAP-funded clinics or programs are expected to provide relevant updates and training to their clinical colleagues who were unable to attend the conference. Comprehensive resources will be made available to facilitate the development of lectures and educational meetings after the conference.

Each RWHAP-funded clinic (whether through Part A, Part B, Part C, Part D, or a combination of any of these) may register up to 3 eligible staff members to attend.

There is no registration fee to attend.

Learning Objectives

The educational objectives for the 2023 RWHAP CLINICAL CONFERENCE are designed and developed based on the identified needs and knowledge gaps of the attendees.

On completion of the 2023 RWHAP CLINICAL CONFERENCE, participants will be able to:

  • Describe the new aspects to the Ryan White HIV/AIDS Program
  • Identify situations in which the choice of antiretroviral regimen should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data on currently available and investigational new antiretroviral drugs, formulations, and strategies
  • Initiate and monitor HIV prevention intervention strategies, including the use of long-acting injectable preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection and in special populations such as adolescents
  • Detect and address practitioner and staff burnout
  • Describe the current best practices of postnatal HIV care and prevention, including issues around breastfeeding
  • Implement key primary care practices
  • Describe the implications of bNAbs vaccines for an HIV vaccine
  • Detect and manage opioid use disorder in people with HIV

IAS-USA Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

American Academy of Family Physicians Credits

The AAFP has reviewed The 2023 Ryan White HIV/AIDS Program CLINICAL CONFERENCE and deemed it acceptable for up to 17.00 Live AAFP Prescribed credits. Term of Approval is from 12/03/2023 to 12/05/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for up to 17 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for up to 17 contact hours (1.7 CEUs) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-23-564-L02-P; 0761-9999-23-565-L02-P; 0761-9999-23-566-L02-P

Conference Funding

This conference is funded by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U1OHA28686.